TTI-1612 (Trillium Therapeutics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTTI-1612 (Trillium Therapeutics)
Drug Alias NamerhHB-EGF
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionHeparin-binding EGF-like growth factor replacements
TargetsHeparin-binding EGF-like growth factor
Therapy Area/IndicationsEnterocolitis, Necrotizing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTrillium Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTrillium Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsEnterocolitis, Necrotizing

Other Information

ATC CodeN/A
Related LinksN/A